Navigation Links
Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome
Date:8/23/2017

PARAMUS, N.J., Aug. 23, 2017 /PRNewswire/ -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for rare and catastrophic forms of genetic epilepsy, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for EPX-300 for the treatment of patients with Dravet Syndrome. Dravet Syndrome qualifies as a rare pediatric disease under Section 529 of the Food, Drug, and Cosmetic Act.

Dravet Syndrome, a lifelong form of epilepsy, begins in the first year of life with frequent or prolonged seizures. Intellectual disability, behavioral abnormalities, gait and motor dysfunction, and increased mortality are commonly observed as the disease progresses. Patients with Dravet Syndrome also suffer with life-threatening seizures that cannot be adequately controlled by available medications. They also face a 15 to 20 percent mortality rate due to SUDEP (Sudden Unexplained Death in Epilepsy), which are commonly seizure-related accidents such as drowning or infections. In most cases, Dravet Syndrome is caused by heterozygous de novo mutations or gene deletions of SCN1A, a gene encoding a brain voltage-gated sodium channel (Nav1.1).

The effectiveness of EPX-300 was discovered using a proprietary phenotype-based zebrafish drug screening platform. The zebrafish harbors 82 percent of human disease-associated genes, and shares many physiological and metabolic pathways with humans. Using the zebrafish model for Dravet Syndrome, drug candidates were identified from a screen of more than 3,000 drugs that suppress seizures and symptoms associated with neurological diseases.

"By receiving orphan drug designation for EPX-300, now all of our drug candidates including EPX-100 and EPX-200, have been granted orphan drug status for Dravet Syndrome from the FDA," says Dr. Hahn-Jun Lee, M.Sc., Ph.D., president and CEO of Epygenix Therapeutics, Inc. "As a result, we are now able to establish a diversified pipeline to support patients with Dravet Syndrome, and are now preparing a clinical testing of our drug candidates for patients as early as possible." 

Dr. Jules Mitchel, Ph.D., president at Target Health, Inc., in New York City, issued a statement: "Working together with Epygenix, the medical community, patients and their families, and the FDA, will allow for a rapid and efficient clinical development path to establish the efficacy and safety of EPX-300 for the treatment of Dravet Syndrome. Congratulations to Epygenix for taking this path where there is an unmet medical need."

Dr. Jack Parent, M.D., and William J Herdman, professor of neurology, co-director of the Comprehensive Epilepsy Center at the University of Michigan Medical School and one of the key scientific advisors of the company, said together that Epygenix has successfully made diversified pipelines to support Dravet Syndrome patients including non-responders to current treatment options. They further hope that EPX-300, together with EPX-100 and EPX-200, will be one of the important treatment options for Dravet Syndrome patients in a near future.

Under the U.S. Orphan Drug Act, the FDA's Office of Orphan Products Development provides sponsors with special status and incentives to facilitate the drug development for rare disease affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides seven years of market exclusivity if the drug candidate receives regulatory approval together with tax credits for qualified clinical trial cost, exemptions from certain FDA application fees, and assistance in clinical trial design.

To learn more about the company and their ongoing work, visit Epygenix.com.

About Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs to treat rare and intractable genetic epilepsy in childhood, such as Dravet Syndrome. Epygenix is currently focused on developing EPX-100, EPX-200 and EPX-300. These drug candidates abolish convulsive behavior and electrographic seizure activity and were discovered in a zebrafish Dravet Syndrome model which mimics the human pathology. For more information, please visit Epygenix.com.

About EPX-300

EPX-300 is an FDA-approved drug for the treatment of major depression disorder which acts via modulation of 5HT signaling pathways. EPX-300 suppressed spontaneous convulsive behavior and electrographic seizures in zebrafish Dravet Syndrome models.

Media Contact

Hahn-Jun Lee, M.Sc., Ph.D.
Phone: 201-724-1786
Email: hahnjun7@epygenix.com

View original content with multimedia:http://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-300-for-the-treatment-of-patients-with-dravet-syndrome-300508283.html


'/>"/>
SOURCE Epygenix Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
Breaking Medicine News(10 mins):